26th Jul 2006 10:00
Hutchison China Meditech Limited26 July 2006 For Immediate Release 26 July 2006 Hutchison China Meditech Limited ("Chi-Med") Notice of Maiden Interim Results Chi-Med, the phamaceutical and healthcare group based primarily in China, willbe announcing its maiden interim results for the six months ended 30 June 2006on Wednesday 9 August 2006. An analyst presentation will be held at 9.30am on the day, at Citigate DeweRogerson, 3 London Wall Buildings, London, EC2M 5SY. Enquiries: Citigate Dewe Rogerson +44 (0)20 7282 1050Yvonne Alexander About Chi-Med Chi-Med is the holding company of a pharmaceutical and healthcare group basedprimarily in China and is listed on the Alternative Investment Market of theLondon Stock Exchange. Chi-Med conducts pharmaceutical research and development of botanical drugs,semi-synthetic natural product drugs, and synthetic single chemical entity drugsthrough its wholly owned Hutchison MediPharma subsidiary. Hutchison MediPharmaaims to bring novel drugs to the global market for the treatment of cancer andauto-immune diseases by using modern drug discovery and development technologiesand clinical standards that meet the requirements of ICH guidelines. Chi-Med is majority owned by Hutchison Whampoa Limited, an internationalcorporation listed on the Main Board of the Hong Kong Stock Exchange. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hutchmed